Most people diagnosed with stage 4 chronic kidney disease (CKD) live for years, not months, and many never progress to the point of needing dialysis at all. The answer depends heavily on your age, the underlying cause of kidney damage, how much protein is leaking into your urine, and whether you’re getting treatment that slows the decline. A large Canadian study found that adults over 75 with stage 4 CKD were far more likely to die of something else entirely than to reach complete kidney failure, while younger adults faced the opposite pattern. This means that the question “how long can I live?” often has a more useful companion: “how likely is it that my kidneys will actually fail before something else gets me?”
What Stage 4 Kidney Disease Means in Practice
Stage 4 CKD means your kidneys are filtering blood at roughly 15 to 29 percent of normal capacity, measured by a number called the estimated glomerular filtration rate (eGFR). That sounds alarming, and it is serious, but it does not mean your kidneys have stopped working. You still produce urine, your body still clears waste, and many people at this stage feel relatively normal day to day, though fatigue, swelling, and changes in appetite are common. Stage 5, which begins below an eGFR of 15, is the point where dialysis or transplantation typically enters the conversation.
One of the most important things to understand is that kidney disease does not always march steadily downhill. A study tracking over 900 patients with advanced CKD found that only about 38 percent showed a steady, linear decline in kidney function. Roughly a quarter followed a curved, less predictable path, another quarter showed no statistically identifiable pattern at all, and about 15 percent actually improved over time.1PubMed Central. Patterns of progression of chronic kidney disease at later stages The average rate of decline was about 3.4 points of eGFR per year, but individual patients ranged wildly, from losing more than 25 points per year to gaining over 15. That range is why blanket survival statistics can be misleading for any one person.
Age Changes the Equation Dramatically
If you are younger than 65 with stage 4 CKD, progressing to kidney failure is a real and likely possibility. But for older adults, the math flips. A large study of Canadian adults with stage 4 CKD found that among people aged 75 to 84, the risk of dying from other causes was about six times higher than the risk of reaching kidney failure. For those 85 and older, it was roughly 25 times higher.2JAMA Network Open. Association of Age With Risk of Kidney Failure in Adults With Stage IV Chronic Kidney Disease in Canada In other words, an 80-year-old with stage 4 CKD is far more likely to live out the rest of their life with damaged but functioning kidneys than to ever sit in a dialysis chair.
This matters because the emotional weight of a stage 4 diagnosis often comes from imagining the worst-case scenario. For older adults especially, the more realistic concern is usually managing the complications that come with reduced kidney function, such as anemia, bone disease, and fluid imbalances, rather than racing to prepare for dialysis.
Proteinuria Is the Single Best Predictor of What Comes Next
Among all the numbers your nephrologist tracks, the amount of protein in your urine is the strongest signal of whether your kidneys will keep declining or hold relatively steady. One study found that patients with normal-range proteinuria had roughly an 80 percent lower risk of disease progression compared to those with elevated protein levels, even after accounting for other factors.3PLoS ONE. Prognosis of chronic kidney disease with normal-range proteinuria: The CKD-ROUTE study Another study confirmed that different ways of measuring protein in the urine, whether from a single spot sample or a full 24-hour collection, all predicted the same composite outcome of death, kidney failure, or disease progression with similar accuracy.4PubMed Central. Predictive value of spot versus 24-hour measures of proteinuria for death, end-stage kidney disease or chronic kidney disease progression
This is practical information you can act on. If your urine protein is low and staying low, your outlook is substantially better than the average stage 4 patient. If it’s high or rising, that’s the clearest alarm bell that aggressive treatment adjustments are needed. Ask your doctor about your urine albumin-to-creatinine ratio at every visit; it’s the single number that most directly answers “is my kidney disease getting worse?”
Using Risk Prediction Tools to Get a Personal Estimate
Doctors now have validated tools that combine your eGFR, age, sex, and urine protein levels into a personalized estimate of your risk of reaching kidney failure within two or five years. The most widely used is the Kidney Failure Risk Equation (KFRE), and it performs well across different causes of kidney disease. In a study of patients with advanced CKD, the four-variable version of this equation distinguished those who would progress to kidney failure from those who wouldn’t with good accuracy at both two-year and five-year time horizons.5PubMed Central. Performance of the Kidney Failure Risk Equation by Disease Etiology in Advanced CKD A separate multicenter validation confirmed similar performance, with the simpler four-variable version outperforming the more complex eight-variable model.6PubMed. Multicenter validation of the Kidney Failure Risk Equation (KFRE) formula in Spanish patients with advanced chronic kidney disease
The KFRE is freely available online. You plug in a few numbers from your latest lab work, and it gives you a percentage risk of needing dialysis or transplant within two or five years. It isn’t perfect, and it tends to slightly overestimate risk for most causes of kidney disease, with the notable exception of polycystic kidney disease, where it has been more accurate.5PubMed Central. Performance of the Kidney Failure Risk Equation by Disease Etiology in Advanced CKD But it gives you something more useful than a generic life-expectancy number: a personalized probability based on your own labs.
Heart Disease Is the Bigger Threat for Many Patients
Kidney disease and heart disease feed on each other. Damaged kidneys accelerate cardiovascular problems through fluid overload, inflammation, and mineral imbalances, while heart failure reduces blood flow to the kidneys and speeds their decline. For patients who have both heart failure and advanced CKD, one study found that the five-year risk of death was about 40 percent higher compared to patients with heart failure alone. Hospital admissions were also significantly more frequent, running about 56 percent higher for all-cause hospitalizations and roughly 25 percent higher for heart-failure-specific admissions in the first year.7PubMed Central. Prognostic Impact of Chronic Kidney Disease in Patients with Heart Failure
This is worth emphasizing because many stage 4 CKD patients focus all their worry on dialysis while underestimating the cardiovascular risk that is statistically more likely to affect them, especially if they are over 65. Controlling blood pressure, managing cholesterol, and treating heart failure aggressively are at least as important as kidney-specific treatments for extending your life at this stage.
Medications That Slow the Decline
Two classes of drugs have the strongest evidence for slowing kidney disease progression, and both are now used in stage 4 CKD.
The first is a group called SGLT2 inhibitors, originally developed for diabetes but now recognized as kidney-protective regardless of whether you have diabetes. These drugs reduce the pressure inside the kidney’s filtering units, which slows damage. A review of the evidence found expanding indications for their use in stage 4 CKD and heart failure, with kidney protection occurring through a mechanism that is separate from their blood-sugar-lowering effect.8PubMed Central. Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations In a study of patients with stage 4 and 5 CKD, those treated with an SGLT2 inhibitor showed stabilized kidney function at 6 and 12 months, with a reduction in urine protein levels suggesting a potential slowing of progression.9Nephrology Dialysis Transplantation. Breaking barriers in nephroprotection for advanced chronic kidney disease: SGLT2 inhibitors in the treatment of CKD Stage 4–5 For patients with type 2 diabetes who had already reached stage 5, SGLT2 inhibitors cut the risk of needing dialysis by about 39 percent compared to matched controls.10Scientific Reports. SGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM
The second class is the older group of blood-pressure drugs that block the renin-angiotensin system, commonly known as ACE inhibitors and ARBs. These have been standard care for kidney disease for decades, but there has been debate about whether to continue them as kidney function drops very low, because they can raise potassium levels and potentially cause a further dip in eGFR. A clinical trial of over 400 patients with advanced CKD found that stopping these drugs did not preserve kidney function any better than continuing them, with kidney failure rates trending higher in the group that stopped. Cardiovascular events and deaths were similar either way.11PubMed. Renin-Angiotensin System Inhibition in Advanced Chronic Kidney Disease The takeaway is that for most people with advanced CKD, staying on these medications under careful monitoring is likely the better choice.
Diet Can Make a Measurable Difference
Reducing protein intake is one of the longest-standing dietary recommendations for slowing kidney disease, and recent evidence suggests the approach works better when combined with supplements called ketoanalogues. These are modified building blocks of protein that provide nutrition while generating less waste for the kidneys to clear. In a study with a median follow-up of nearly three years, patients on a low-protein diet supplemented with ketoanalogues had a 76 percent lower risk of significant kidney function decline and a 76 percent lower rate of dialysis initiation compared to those on a low-protein diet alone. The yearly rate of eGFR decline was roughly 4.5 points with the supplements versus nearly 8 points without them.12PubMed Central. The role of a low protein diet supplemented with ketoanalogues on kidney progression in pre-dialysis chronic kidney disease patients
Even in very elderly patients, this approach shows promise. A pilot study of patients in their 90s with advanced CKD found that a low-protein diet with ketoanalogues improved eGFR from about 18 to 24 over the study period, while also cutting their estimated two-year risk of kidney failure from about 34 percent to 15 percent. This happened without causing malnutrition, which is the main concern with restricting protein in older adults.13PubMed. Effects of low protein diet supplemented with ketoanalogues on kidney function and nutritional outcomes in a nonagenarian population with advanced chronic kidney disease These are small studies and the approach requires guidance from a renal dietitian, but the direction of the evidence is encouraging.
Treating Metabolic Acidosis Protects Remaining Kidney Function
As kidneys lose function, they struggle to clear acid from the bloodstream, and this buildup accelerates further kidney damage in a vicious cycle. Treating this acid buildup, often with something as simple as sodium bicarbonate (essentially baking soda in a measured dose), has shown real benefits. A meta-analysis of several trials found that oral bicarbonate better preserved kidney function compared to standard care, and the UBI study specifically showed that patients receiving sodium bicarbonate had lower rates of reaching the point where kidney function halved and lower rates of dialysis initiation.14PubMed Central. Metabolic Acidosis in Chronic Kidney Disease: Pathogenesis, Clinical Consequences, and Treatment
In a landmark randomized study of patients with stage 4 or 5 CKD and low bicarbonate levels, those treated with sodium bicarbonate had a dramatically lower risk of progressing to end-stage disease compared to controls after two years of follow-up. Another trial of patients with stage 3 or 4 CKD found that those treated with sodium citrate for two years maintained higher eGFR values and lower protein in their urine than those who did not receive treatment.15American Journal of Kidney Diseases. Metabolic Acidosis in Chronic Kidney Disease: Core Curriculum 2019 Interestingly, increasing fruit and vegetable intake, which provides natural alkali, has also been shown to help. If your blood bicarbonate level is below normal, this is a treatable problem that directly affects how fast your kidneys decline.
If Kidneys Do Fail, Dialysis Versus Conservative Care
For patients whose kidneys decline past stage 4 into stage 5, the traditional next step has been dialysis. But the survival advantage of dialysis is not as clear-cut as many people assume, especially for older or frailer adults. A Cochrane review pooling data from 23 studies and nearly 25,000 participants found that conservative kidney management, meaning symptom-focused care without dialysis, was associated with higher death rates compared to dialysis overall. But the certainty of this evidence was rated very low, and the effects on cardiovascular death, hospitalization, and quality of life were all uncertain.16PubMed Central. Conservative kidney management versus dialysis for stage 5 chronic kidney disease in older people
A separate review found that the survival benefit of dialysis mainly appeared in younger, less frail patients, and that this advantage diminished as patients became older and sicker with multiple conditions. Patients managed conservatively tended to report comparable or better quality of life and spent fewer days in the hospital.17PubMed Central. Dialysis versus conservative kidney management in older adults: why one size does not fit all For an 85-year-old with heart failure and limited mobility, starting dialysis may add weeks or months of life at the cost of significantly more time in hospitals and clinics. This is a deeply personal decision, and the evidence increasingly supports the idea that choosing not to start dialysis can be a rational, medically sound decision for the right patient.
For patients managed conservatively, a narrative review of studies on older adults found that median survival ranged widely, from 1 to 45 months, with one-year survival rates spanning from about 29 to 82 percent depending on the population studied.18PubMed Central. Survival of Older Patients With Advanced CKD Managed Without Dialysis: A Narrative Review That enormous range underscores how much the individual patient’s overall health matters compared to the kidney numbers alone.
Transplantation at Stage 4
Kidney transplantation remains the treatment that offers the best long-term outcomes for patients who are candidates, and there is growing interest in performing transplants before a patient ever starts dialysis, a strategy called preemptive transplantation. Among older patients over 65 who received a transplant, those who received it preemptively had a three-year patient survival rate of about 83 to 90 percent, depending on the quality of the donor kidney, compared to similar survival with slightly lower rates in those who started dialysis first.19American Journal of Transplantation. Evaluating Outcomes of Preemptive Kidney Transplant in Patients over 65 Using High-KDPI Kidneys Compared to Non-Preemptive Recipients
There has been some concern that preemptive transplants might carry higher mortality, since a study initially found higher death rates in preemptive recipients. But after adjusting for age, body weight, donor type, and other comorbidities, the difference disappeared entirely, suggesting the early mortality signal was driven by the fact that preemptive recipients tended to be older and sicker, not by the timing of the transplant itself.20PubMed Central. Comparison of survival outcomes in preemptive versus non-preemptive kidney transplant recipients If you are in stage 4 and a potential transplant candidate, early referral for transplant evaluation is worth discussing with your nephrologist even if dialysis still feels far away.
The Hidden Danger of Too Many Medications
By stage 4 CKD, most patients are taking a long list of medications: blood pressure drugs, diabetes medications, phosphate binders, bicarbonate supplements, statins, and often more. This polypharmacy creates its own set of risks. A systematic review found that taking many medications was independently associated with higher death rates, faster kidney function decline, more adverse drug reactions, and lower quality of life in CKD patients.21PubMed Central. Polypharmacy in Patients with CKD: A Systematic Review and Meta-Analysis The irony is painful: each individual medication may be justified, but the combination can become harmful.
The interactions are not hypothetical. Research has found that drug interactions involving heart-rhythm changes, dangerously high potassium, and excessive bleeding are common in older adults with CKD and frequently lead to emergency treatment or rehospitalization.22PubMed. Adverse Drug Events in Patients with Chronic Kidney Disease Associated with Multiple Drug Interactions and Polypharmacy If you’re taking more than five or six medications, it’s reasonable to ask your doctor for a formal medication review, where each drug is weighed against the risk it adds in combination. Sometimes stopping one medication can do more good than adding another.
Why the Cause of Your Kidney Disease Matters
Not all stage 4 CKD is created equal. Diabetes-related kidney disease tends to progress more rapidly and severely than other causes. Kidney disease in diabetic patients can accelerate through pathways that non-diabetic kidney disease does not, and it often coexists with damage to the eyes, nerves, and blood vessels that further complicates management.23PubMed Central. Diabetic Kidney Disease: A Syndrome Rather Than a Single Disease On the other end of the spectrum, some causes like certain types of chronic inflammation or hypertension-related damage may plateau or respond well to treatment. Even the KFRE risk equation, despite performing well overall, calibrates slightly differently depending on what caused the kidney disease, underestimating risk somewhat for polycystic kidney disease while overestimating it for others.5PubMed Central. Performance of the Kidney Failure Risk Equation by Disease Etiology in Advanced CKD
Socioeconomic and Racial Disparities in Outcomes
Your zip code and income affect your kidney disease trajectory in ways that feel unfair because they are. A study of adults with hypertension or diabetes found that Black participants had a higher incidence of CKD compared to white participants. About 10 percent of this disparity was explained by poorer access to healthcare, while over 60 percent was tied to a combination of demographic, socioeconomic, lifestyle, and clinical factors.24PubMed Central. Socioeconomic Disparities in Chronic Kidney Disease Lower income is associated with later diagnosis, less access to specialists, and lower rates of transplant referral, all of which worsen outcomes that would have been preventable with earlier and more equitable care.
These disparities matter practically because they are modifiable. If you are in a lower-income area or a community historically underserved by the healthcare system, being proactive about getting a nephrology referral, understanding your lab numbers, and asking about every treatment option described in this article becomes even more important. The biology of kidney disease does not discriminate, but the system around it often does.